CURRICULUM VITAE

**Name:** Kyeung Min Joo (주경민)

**Address:** Department of Anatomy and Cell Biology

Sungkyunkwan University School of Medicine

Graduate School for Health Sciences & Technology

Samsung Advanced Institute for Health Science & Technology

Sungkyunkwan University School of Medicine

2066 Seobu-ro, Jangan-gu, Suwon, Gyeonggi-do, South Korea 16419

Tel: +82-31-299-6073

Fax: +82-31-299-6029

Mobile: +82-10-7633-0683

E-mail: kmjoo@skku.edu

**Education:**

1996-2002 B.S. (M.D.)

Seoul National University College of Medicine in Seoul, South Korea

2002-2006 Ph.D. (Medicine, Neuroscience)

Seoul National University College of Medicine in Seoul, South Korea

Under the supervision of Dr. Choong Ik Cha

 Thesis: Distribution of vasoactive intestinal peptide and pituitary

adenylate cyclase-activating polypeptide receptors

(VPAC1, VPAC2, and PAC1 receptor) in the rat brain and

their expressional changes during aging

**Certificate:**

2002 Medical doctor (South Korea, No. 77169)

**Experiences:**

2002-2006 Teaching Assistant

Seoul National University College of Medicine in Seoul, South Korea

2006-2009 Public Health Doctor (Obligated Military Service Program)

 Division of Forensic Medicine, Department of Forensic Medicine

National Institute for Scientific Investigation, Seoul, South Korea

2006-2009 Postdoctoral fellow with Dr. Do-Hyun Nam

Department of Neurosurgery, Cancer Stem Cell Research Center

 Samsung Biomedical Research Institute, Samsung Medical Center

2009-2012 Assistant professor

 Department of Anatomy

Seoul National University College of Medicine in Seoul, South Korea

2012-2013 Assistant professor

 Department of Anatomy and Cell Biology

Sungkyunkwan University School of Medicine

2013-2018 Associate professor

 Department of Anatomy and Cell Biology

Sungkyunkwan University School of Medicine

2015-2016 Visiting research scholar

 Department of Radiation Oncology

 Duke University Medical Center

2018-Present Professor

 Department of Anatomy and Cell Biology

Sungkyunkwan University School of Medicine

2018-Present CEO

 Medinno Inc. (Company for neural stem cell therapeutics)

**Awards or Honors:**

2004 Excellent poster award in the 54th annual conference

of the Korean association of anatomists

2008 Travel award in the 6th ISSCR annual meeting

of the International society for stem cell research

2009 Hoshino award in the 3rd quadrennial meeting of the world federation

of neuro-oncology jointly with the 6th meeting of the asian society for

neuro-oncology (ASNO)

2012 Scientist of the year, Korean Association of Anatomist

**Publications:**

1. Kim SS, Pyeon HJ, Bae YK, Nam H, Kim CK, Lee SH, **Joo KM**. Adult Human Multipotent Neural Cells Could Be Distinguished from Other Cell Types by Proangiogenic Paracrine Effects via MCP-1 and GRO. Stem Cells Int. 2021 Aug 12;2021:6737288.
2. Lee S, **Joo KM**, Park K. Challenging Microvascular Decompression Surgery for Hemifacial Spasm. World Neurosurg. 2021 Jul;151:e94-e99.
3. Won JS, Yeon JY, Pyeon HJ, Noh YJ, Hwang JY, Kim CK, Nam H, Lee KH, Lee SH, **Joo KM**. Optimal Preclinical Conditions for Using Adult Human Multipotent Neural Cells in the Treatment of Spinal Cord Injury. Int J Mol Sci. 2021 Mar 4;22(5):2579.
4. Lee HW, Chung W, Lee HO, Jeong DE, Jo A, Lim JE, Hong JH, Nam DH, Jeong BC, Park SH,**Joo KM**, Park WY. Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. Genome Med. 2020 May 27;12(1):47. (**co-corresponding author**)
5. Lee YI, Kim YG, Pyeon HJ, Ahn JC, Logan S, Orock A, **Joo KM**, Lőrincz A, Deák F. Dysregulation of the SNARE-binding protein Munc18-1 impairs BDNF secretion and synaptic neurotransmission: a novel interventional target to protect the aging brain. Geroscience. 2019 Apr;41(2):109-123.
6. Yun JW, Bae YK, Cho SY, Koo H, Kim HJ, Nam DH, Kim SH, Chun S, **Joo KM**, Park WY. Elucidation of Novel Therapeutic Targets for Acute Myeloid Leukemias with RUNX1-RUNX1T1 Fusion. Int J Mol Sci. 2019 Apr 6;20(7):1717. (**co-corresponding author**)
7. Yeon JY, Hwang JY, Lee HW, Pyeon HJ, Won JS, Noh YJ, Nam H, **Joo KM**. Optimized Clump Culture Methods for Adult Human Multipotent Neural Cells. Int J Mol Sci. 2018 Oct 29;19(11): 3380. (**co-corresponding author**)
8. Won JS, Nam H, Lee HW, Hwang JY, Noh YJ, Nam DH, Lee SH, **Joo KM**. In vivo distribution of U87MG cells injected into the lateral ventricle of rats with spinal cord injury. PLoS One. 2018 Aug 16;13(8):e0202307. (**co-corresponding author**)
9. Lee KH, Pyeon HJ, Nam H, Won JS, Hwang JY, Lee KA, Yeon JY, Hong SC, Nam DH, Lee K, Lee SH, **Joo KM**. Significant therapeutic effects of adult human multipotent neural cells on spinal cord injury. Stem Cell Res. 2018 Aug;31:71-78. (**co-corresponding author**)
10. Sa JK, Kim SH, Lee JK, Cho HJ, Shin YJ, Shin H, Koo H, Kim D, Lee M, Kang W, Hong SH, Kim JY, Park YW, Song SW, Lee SJ, **Joo KM**, Nam DH. Identification of Genomic and Molecular Traits that Present Therapeutic Vulnerability to HGF-targeted therapy in Glioblastoma. Neuro Oncol. 2018 Jun 23;21(2):222-33.
11. Lee KH, Nam H, Won JS, Hwang JY, Jang HW, Lee SH, **Joo KM**. In Vivo Spinal Distribution of Cy5.5 Fluorescent Dye after Injection via the Lateral Ventricle and Cisterna Magna in Rat Model. J Korean Neurosurg Soc. 2018 Jul;61(4):434-40. (**co-corresponding author**)
12. Jeong DE, Woo SR, Nam H, Nam DH, Lee JH, **Joo KM**. Preclinical and clinical implications of TERT promoter mutation in glioblastoma multiforme. Oncol Lett. 2017 Dec;14(6):8213-19. (**co-corresponding author**)
13. Yoon SW, Cramer CK, Miles DA, Reinsvold MH, **Joo KM**, Kirsch DG, Oldham M. A precision 3D conformal treatment technique in rats: application to whole brain radiotherapy with hippocampal avoidance. Med Phys. 2017 Nov;44(11):6008-17.
14. Bae YK, Kim GH, Lee JC, Seo BM, **Joo KM**, Lee G, Nam H. The Significance of SDF-1α-CXCR4 Axis in in vivo Angiogenic Ability of Human Periodontal Ligament Stem Cells. Mol Cells. 2017 Jun 30;40(6):386-92.
15. Nam H, Kim GH, Bae YK, Jeong DE, **Joo KM**, Lee K, Lee SH. Angiogenic Capacity of Dental Pulp Stem Cell Regulated by SDF-1α-CXCR4 Axis. Stem Cells Int. 2017;2017:8085462.
16. Lee YE, Choi SA, Kwack PA, Kim HJ, Kim IH, Wang KC, Phi JH, Lee JY, Chong S, Park SH, Park KD, Hwang DW, **Joo KM**, Kim SK. Repositioning disulfiram as a radiosensitizer against atypical teratoid/rhabdoid tumor. Neuro Oncol. 2017 Aug 1;19(8):1079-87. (**co-corresponding author**)
17. Lee KH, Nam H, Jeong da E, Kim SS, Song HJ, Pyeon HJ, Kang K, Hong SC, Nam DH, **Joo KM**. Sensitive Tumorigenic Potential Evaluation of Adult Human Multipotent Neural Cells Immortalized by hTERT Gene Transduction. PLoS One. 2016 Jul 8;11(7):e0158639. (**corresponding author**)
18. Choi SA, Yun JW, **Joo KM**, Lee JY, Kwak PA, Lee YE, You JR, Kwon E, Kim WH, Wang KC, Phi JH, Kang BC, Kim SK. Preclinical Biosafety Evaluation of Genetically Modified Human Adipose Tissue-Derived Mesenchymal Stem Cells for Clinical Applications to Brainstem Glioma. Stem Cells Dev. 2016 Jun 15;25(12):897-908. (**co-first author**)
19. Kim KT, Lee HW, Lee HO, Song HJ, Jeong da E, Shin S, Kim H, Shin Y, Nam DH, Jeong BC, Kirsch DG, **Joo KM**, Park WY. Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma. Genome Biol. 2016 Apr 29;17(1):80. (**co-corresponding author**)
20. Hwang SJ, Lee HW, Kim HR, Lee H, Shin CH, Yun SI, Lee DH, Kim DH, Kim KK, **Joo KM**, Kim HH. Ubiquitin-specific protease 4 controls metastatic potential through β-catenin stabilization in brain metastatic lung adenocarcinoma. Sci Rep. 2016 Feb 17;6:21596. (**co-corresponding author**)
21. Cho YJ, Kang W, Kim SH, Sa JK, Kim N, Paddison PJ, Kim M, **Joo KM**, Hwang YI, Nam DH. Involvement of DDX6 gene in radio- and chemoresistance in glioblastoma. Int J Oncol. 2016 Mar;48(3):1053-62.
22. Lee JK, Chang N, Yoon Y, Yang H, Cho H, Kim E, Shin Y, Kang W, Oh YT, Mun GI, **Joo KM**, Nam DH, Lee J. USP1 targeting impedes GBM growth by inhibiting stem cell maintenance and radioresistance. Neuro Oncol. 2016 Jan;18(1):37-47.
23. Lee SJ, Kang WY, Yoon Y, Jin JY, Song HJ, Her JH, Kang SM, Hwang YK, Kang KJ, **Joo KM**, Nam DH. Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain. BMC Cancer. 2015 Dec 24;15(1):1011. (**co-corresponding author**)
24. Lee YE, An J, Lee KH, Kim SS, Song HJ, Pyeon H, Nam H, Kang K, **Joo KM**. The Synergistic Local Immunosuppressive Effects of Neural Stem Cells Expressing Indoleamine 2,3-Dioxygenase (IDO) in an Experimental Autoimmune Encephalomyelitis (EAE) Animal Model. PLoS One. 2015 Dec 4;10(12):e0144298. (**co-corresponding author**)
25. Cramer CK, Yoon SW, Reinsvold M, **Joo KM**, Norris H, Hood RC, Adamson JD, Klein RC, Kirsch DG, Oldham M. Treatment Planning and Delivery of Whole Brain Irradiation with Hippocampal Avoidance in Rats. PLoS One. 2015 Dec 4;10(12):e0143208.
26. Lee Y, Kim KH, Kim DG, Cho HJ, Kim Y, Rheey J, Shin K, Seo YJ, Choi YS, Lee JI, Lee J, **Joo KM**, Nam DH. FoxM1 Promotes Stemness and Radio-Resistance of Glioblastoma by Regulating the Master Stem Cell Regulator Sox2. PLoS One. 2015 Oct 7;10(10):e0137703. (**co-corresponding author**)
27. Jeong da E, Song HJ, Lim S, Lee SJ, Lim JE, Nam DH, **Joo KM**, Jeong BC, Jeon SS, Choi HY, Lee HW. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis. Oncotarget. 2015 Oct 20;6(32):33046-64.
28. Kim J, Lee IH, Cho HJ, Park CK, Jung YS, Kim Y, Nam SH, Kim BS, Johnson MD, Kong DS, Seol HJ, Lee JI, **Joo KM**, Yoon Y, Park WY, Lee J, Park PJ, Nam DH. Spatiotemporal Evolution of the Primary Glioblastoma Genome. Cancer Cell. 2015 Sep 14;28(3):318-28.
29. Kang W, Kim SH, Cho HJ, Jin J, Lee J, **Joo KM**, Nam DH. Talin1 targeting potentiates anti-angiogenic therapy by attenuating invasion and stem-like features of glioblastoma multiforme. Oncotarget. 2015 Sep 29;6(29):27239-51. (**co-corresponding author**)
30. Kim DG, Jin Y, Jin J, Yang H, **Joo KM**, Lee WS, Shim SR, Kim SW, Yoo J, Lee SH, Yoo JS, Nam DH. Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis. MAbs. 2015;7(6):1195-204.
31. Kim KT, Lee HW, Lee HO, Kim SC, Seo YJ, Chung W, Eum HH, Nam DH, Kim J, **Joo KM**, Park WY. Single-cell mRNA sequencing identifies subclonal heterogeneity in anti-cancer drug responses of lung adenocarcinoma cells. Genome Biol. 2015 Jun 19;16:127. (**co-corresponding author**)
32. Sa JK, Yoon Y, Kim M, Kim Y, Cho HJ, Lee JK, Kim GS, Han S, Kim WJ, Shin YJ, **Joo KM**, Paddison PJ, Ishitani T, Lee J, Nam DH. In vivo RNAi screen identifies NLK as a negative regulator of mesenchymal activity in Glioblastoma. Oncotarget. 2015 Aug 21;6(24):20145-59.
33. Choi SA, Lee YE, Kwak PA, Lee JY, Kim SS, Lee SJ, Phi JH, Wang KC, Song J, Song SH, **Joo KM**, Kim SK. Clinically applicable human adipose tissue-derived mesenchymal stem cells delivering therapeutic genes to brainstem gliomas. Cancer Gene Ther. 2015 Jun;22(6):302-11. (**co-corresponding author**)
34. Hwang SJ, Lee HW, Kim HR, Song HJ, Lee DH, Lee H, Shin CH, Joung JG, Kim DH, **Joo KM**, Kim HH. Overexpression of microRNA-95-3p suppresses brain metastasis of lung adenocarcinoma through downregulation of cyclin D1. Oncotarget. 2015 Aug 21;6(24):20434-48. (**co-corresponding author**)
35. Woo SR, Oh YT, An JY, Kang BG, Nam DH, **Joo KM**. Glioblastoma specific antigens, GD2 and CD90, are not involved in cancer stemness. Anat Cell Biol. 2015 Mar;48(1):44-53. (**corresponding author**)
36. Lee HW, Choi HY, **Joo KM**, Nam DH. Tumor Progression Locus 2 (Tpl2) Kinase as a Novel Therapeutic Target for Cancer: Double-Sided Effects of Tpl2 on Cancer. Int J Mol Sci. 2015 Feb 25;16(3):4471-91. Review. (**co-corresponding author**)
37. Nam H, Lee KH, Nam DH, **Joo KM**. Adult human neural stem cell therapeutics: Current developmental status and prospect. World J Stem Cells. 2015 Jan 26;7(1):126-36. Review. (**corresponding author**)
38. Lee HW, Lee JI, Lee SJ, Cho HJ, Song HJ, Jeong DE, Seo YJ, Shin S, Joung JG, Kwon YJ, Choi YL, Park WY, Lee HM, Seol HJ, Shim YM, **Joo KM**, Nam DH. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy. Clin Cancer Res. 2015 Mar 1;21(5):1172-82. (**co-corresponding author**)
39. Lee JK, **Joo KM**, Lee J, Yoon Y, Nam DH. Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling. Onco Targets Ther. 2014 Oct 20;7:1933-44. Review.
40. Woo SR, Ham Y, Kang W, Yang H, Kim S, Jin J, **Joo KM**, Nam DH. KML001, a Telomere-Targeting Drug, Sensitizes Glioblastoma Cells to Temozolomide Chemotherapy and Radiotherapy through DNA Damage and Apoptosis. Biomed Res Int. 2014;2014:747415. (**co-corresponding author**)
41. Lee HW, Cho HJ, Lee SJ, Song HJ, Cho HJ, Park MC, Seol HJ, Lee JI, Kim S, Lee HM, Choi HY, Nam DH, **Joo KM**. Tpl2 induces castration resistant prostate cancer progression and metastasis. Int J Cancer. 2015 May 1;136(9):2065-77.
42. Oh YT, Cho HJ, Kim J, Lee JH, Rho K, Seo YJ, Choi YS, Jung HJ, Song HS, Kong DS, Seol HJ, Lee JI, Yoon Y, Kim S, Nam DH, **Joo KM**. Translational validation of personalized treatment strategy based on genetic characteristics of glioblastoma. PLoS One. 2014 Aug 1;9(8):e103327
43. Kim J, Lee Y, Cho HJ, Lee YE, An J, Cho GH, Ko YH, Joo KM, Nam DH. NTRK1 fusion in glioblastoma multiforme. PLoS One. 2014 Mar 19;9(3):e91940. (**co-corresponding author**)
44. Cho YB, Hong HK, Choi YL, Oh E, **Joo KM**, Jin J, Nam DH, Ko YH, Lee WY. Colorectal cancer patient-derived xenografted tumors maintain characteristic features of the original tumors. J Surg Res. 2014 Apr;187(2):502-9.
45. Kang W, Jin J, Yang H, Seol HJ, Kim KH, Lee JI, Kim SU, **Joo KM**, Nam DH. Genetically-engineered human neural stem cells with rabbit carboxyl esterase can target CNS lymphoma. Anticancer Res. 2013 Dec;33(12):5335-42. (**co-corresponding author**)
46. Lee HW, Park YM, Lee SJ, Cho HJ, Kim DH, Lee JI, Kang MS, Seol HJ, Shim YM, Nam DH, Kim HH, **Joo KM**. Alpha-smooth muscle actin (ACTA2) is required for metastatic potential of human lung adenocarcinoma. Clin Cancer Res. 2013 Nov 1;19(21):5879-89.
47. Lee HW, **Joo KM**, Lim JE, Cho HJ, Cho HJ, Park MC, Seol HJ, Seo SI, Lee JI, Kim S, Jeong BC, Nam DH. Tumor Progression Locus 2 (Tpl2) Kinase Contributes Tumor Growth and Metastasis of Clear Cell Renal Cell Carcinoma. Mol Cancer Res. 2013 Nov;11(11):1375-86. (**co-first author**)
48. Kang W, Seol HJ, Seong DH, Kim J, Kim Y, Kim SU, Nam DH, **Joo KM**. Adenosine potentiates the therapeutic effects of neural stem cells expressing cytosine deaminase against metastatic brain tumors. Oncol Rep. 2013 Sep;30(3):1101-6.
49. Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, Oh YT, Kim H, Rheey J, Nakano I, Lee C, **Joo KM**, Rich JN, Nam DH, Lee J. Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-like Cells. Cancer Cell. 2013 Jun 10;23(6):839-52
50. Lee SJ, Seol HJ, Lee HW, Kang WY, Kang BG, Jin J, Jo MY, Jin Y, Lee JI, Joo KM, Nam DH. Gene silencing of c-Met leads to brain metastasis inhibitory effects. Clin Exp Metastasis. 2013 Oct;30(7):845-54. (**co-corresponding author**)
51. Yang H, Lee HW, Kim Y, Lee Y, Choi YS, Kim KH, Jin J, Lee J, **Joo KM**, Nam DH. Radiosensitization of brain metastasis by targeting c-MET. Lab Invest. 2013 Mar;93(3):344-53. (**co-corresponding author**)
52. **Joo KM**, Kim J, Jin J, Kim M, Seol HJ, Muradov J, Yang H, Choi YL, Park WY, Kong DS, Lee JI, Ko YH, Woo HG, Lee J, Kim S, Nam DH. Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. Cell Rep. 2013 Jan 31;3(1):260-73.
53. Kim KH, Seol HJ, Kim EH, Rheey J, Jin HJ, Lee Y, **Joo KM**, Lee J, Nam DH. Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells. Neuro Oncol. 2013 Feb;15(2):161-71.
54. **Joo KM**, Kang BG, Yeon JY, Cho YJ, An JY, Song HS, Won JH, Kim SJ, Hong SC, Nam DH. Experimental and clinical factors influencing long-term stable in vitro expansion of multipotent neural cells from human adult temporal lobes. Exp Neurol. 2013 Feb;240:168-77.
55. Lee HW, Seol HJ, Choi YL, Ju HJ, **Joo KM**, Ko YH, Lee JI, Nam DH. Genomic copy number alterations associated with the early brain metastasis of non-small cell lung cancer. Int J Oncol. 2012 Dec;41(6):2013-20.
56. Lee JC, **Joo KM**, Choe SY, Cha CI.Region-specific changes in the immunoreactivity of TRPV4 expression in the central nervous system of SOD1(G93A) transgenic mice as an in vivo model of amyotrophic lateral sclerosis. J Mol Histol. 2012 Dec;43(6):625-31.
57. **Joo KM,** Jin J, Kim E, Kim KH, Kim Y, Kang BG, Kang YJ, Lathia JD, Cheng KH, Song P, Kim H, Seol HJ, Kong DS, Lee JI, Rich JN, Lee J, Nam DH. MET Signaling Regulates Glioblastoma Stem Cells. Cancer Res. 2012 Aug 1;72(15):3828-3838.
58. Cho YJ, Song HS, Bhang S, Lee S, Kang BG, Lee JC, An J, Cha CI, Nam DH, Kim BS, **Joo KM**. Therapeutic effects of human adipose stem cell-conditioned medium on stroke. J Neurosci Res. 2012 Sep;90(9):1794-802.
59. Jo MY, Kim YG, Kim Y, Lee SJ, Kim MH, **Joo KM**, Kim HH, Nam DH. Combined therapy of temozolomide and ZD6474 (vandetanib) effectively reduces glioblastoma tumor volume through anti-angiogenic and anti-proliferative mechanisms. Mol Med Report. 2012 Jul;6(1):88-92.
60. **Joo KM**, Jin J, Kang BG, Lee SJ, Kim KH, Yang H, Lee YA, Cho YJ, Im YS, Lee DS, Lim DH, Kim DH, Um HD, Lee SH, Lee JI, Nam DH. Trans-differentiation of neural stem cells: a therapeutic mechanism against the radiation induced brain damage. PLoS One. 2012;7(2):e25936.
61. Seol HJ, Yoo HY, Jin J, **Joo KM**, Kim HS, Yoon SJ, Choi SH, Kim Y, Pyo HR, Lim DH, Kim W, Um HD, Kim JH, Lee JI, Nam DH. The expression of DNA damage checkpoint proteins and prognostic implication in metastatic brain tumors. Oncol Res. 2011;19(8-9):381-90.
62. Lee JC, Seong J, Kim SH, Lee SJ, Cho YJ, An J, Nam DH, **Joo KM**, Cha CI. Replacement of microglial cells using Clodronate liposome and bone marrow transplantation in the central nervous system of SOD1(G93A) transgenic mice as an in vivo model of amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2012 Feb 10;418(2):359-65. (**co-corresponding author**)
63. Jung Y, **Joo KM**, Seong DH, Choi YL, Kong DS, Kim Y, Kim MH, Jin J, Suh YL, Seol HJ, Shin CS, Lee JI, Kim JH, Song SY, Nam DH. Identification of prognostic biomarkers for glioblastomas using protein expression profiling. Int J Oncol. 2012 Apr;40(4):1122-32. (**co-first author**)
64. Kim Y, Kim KH, Lee J, Lee YA, Kim M, Lee SJ, Park K, Yang H, Jin J, **Joo KM**, Lee J, Nam DH. Wnt activation is implicated in glioblastoma radioresistance. Lab Invest. 2012 Mar;92(3):466-73.
65. Jin J, Bae KH, Yang H, Lee SJ, Kim H, Kim Y, **Joo KM**, Seo SW, Park TG, Nam DH. In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles. Bioconjug Chem. 2011 Dec 21;22(12):2568-72.
66. Seol HJ, Jin J, Seong DH, **Joo KM**, Kang W, Yang H, Kim J, Shin CS, Kim Y, Kim KH, Kong DS, Lee JI, Aboody KS, Lee HJ, Kim SU, Nam DH. Genetically engineered human neural stem cells with rabbit carboxyl esterase can target brain metastasis from breast cancer. Cancer Lett. 2011 Dec 8;311(2):152-9.
67. Cho YJ, Lee JC, Kang BG, An J, Song HS, Son O, Nam DH, Cha CI, **Joo KM**. Immunohistochemical study on the expression of calcium binding proteins (calbindin-D28k, calretinin, and parvalbumin) in the cerebral cortex and in the hippocampal region of nNOS knock-out(-/-) mice. Anat Cell Biol. 2011 Jun;44(2):106-15.
68. Kim KH, Yoo HY, **Joo KM**, Jung Y, Jin J, Kim Y, Yoon SJ, Choi SH, Seol HJ, Park WY, Nam DH. Time-course analysis of DNA-damage response-related genes after in vitro radiation in H460 and H1229 lung cancer cell lines. Exp Mol Med. 2011 Jul 30;43(7):419-26. (**co-first author**)
69. Seol HJ, Yoo HY, Jin J, **Joo KM**, Kong DS, Yoon SJ, Yang H, Kang W, Lim DH, Park K, Kim JH, Lee JI, Nam DH. Prognostic implications of the DNA damage response pathway in glioblastoma. Oncol Rep. 2011 Aug;26(2):423-30.
70. Jin X, Jeon HY, **Joo KM**, Kim JK, Jin J, Kim SH, Kang BG, Beck S, Lee SJ, Kim JK, Park AK, Park WY, Choi YJ, Nam DH, Kim H. Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation. Cancer Res. 2011 Apr 15;71(8):3066-75. (**co-first author**)
71. Lee SJ, Kim Y, Jo MY, Kim HS, Jin Y, Kim SU, Jin J, **Joo KM**, Nam DH. Combined treatment of tumor-tropic human neural stem cells containing the CD suicide gene effectively targets brain tumors provoking a mild immune response. Oncol Rep. 2011 Jan;25(1):63-8. (**co-corresponding author**)
72. Jin J, **Joo KM**, Lee SJ, Jo MY, Kim Y, Jin Y, Kim JK, Ahn JM, Yoon MJ, Lim J, Nam DH. Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma. Oncol Rep. 2011 Jan;25(1):33-9. (**co-first author**)
73. Lee JC, Jin Y, Jin J, Kang BG, Nam DH, **Joo KM**, Cha CI. Functional neural stem cell isolation from brains of adult mutant SOD1 (SOD1(G93A)) transgenic amyotrophic lateral sclerosis (ALS) mice. Neurol Res. 2011 Jan;33(1):33-7. (**co-corresponding author**)
74. Kim CK, Nguyen TL, **Joo KM**, Nam DH, Park J, Lee KH, Cho SW, Ahn JY. Negative regulation of p53 by the long isoform of ErbB3 binding protein Ebp1 in brain tumors. Cancer Res. 2010 Dec 1;70(23):9730-41. (**co-first author**)
75. Lee JC, Cho YJ, Kim J, Kim N, Kang BG, Cha CI, **Joo KM**. Region-specific changes in the immunoreactivity of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC2, and PAC1 receptor) in the aged rat brains. Brain Res. 2010 Sep 10;1351:32-40.
76. Lee JC, Chung YH, Cho YJ, Kim J, Kim N, Cha CI, **Joo KM**. Immunohistochemical study on the expression of calcium binding proteins (calbindin-D28k, calretinin, and parvalbumin) in the cerebellum of the nNOS knock-out(-/-) mice. Anat Cell Biol. 2010 Mar;43(1):64-71.
77. Oh K, **Joo KM**, Jung YS, Lee J, Kang H, Lee HY, Lee DS. A receptor-independent, cell-based JAK activation assay for screening for JAK3-specific inhibitors. J Immunol Methods. 2010 Mar 31;354(1-2):45-52.
78. Jin J, **Joo KM**, Nam Y, Kim DH, Lee SJ, Jo MY, Jin Y, Kim HS, Seo SW, Kim SJ, Nam DH, Kim WS. Schedule-dependent synergistic effect of rituximab on methotrexate chemotherapy against lymphoma of the central nervous system. Exp Ther Med. 2010 Nov;1(6):943-946. (**co-first author**)
79. **Joo KM**, Nam DH. Prospective identification of cancer stem cells with the surface antigen CD133. Methods Mol Biol. 2009;568:57-71.
80. Kim Y, **Joo KM**, Jin J, Nam DH. Cancer stem cells and their mechanism of chemo-radiation resistance. Int J Stem Cells. 2009 May;2(2):109-14. Review
81. **Joo KM**, Park IH, Shin JY, Jin J, Kang BG, Kim MH, Lee SJ, Jo MY, Kim SU, Nam DH. Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases. Mol Ther. 2009 Mar;17(3):570-5.
82. Kong DS, Song SY, Kim DH, **Joo KM**, Yoo JS, Koh JS, Dong SM, Suh YL, Lee JI, Park K, Kim JH, Nam DH. Prognostic significance of c-Met expression in glioblastomas. Cancer. 2009 Jan 1;115(1):140-8.
83. **Joo KM**, Song SY, Park K, Kim MH, Jin J, Kang BG, Jang MJ, Lee GS, Kim MS, Nam DH. Response of brain specific microenvironment to P-glycoprotein inhibitor: An important factor determining therapeutic effect of P-glycoprotein inhibitor on brain metastatic tumors. Int J Oncol. 2008 Oct;33(4):705-12.
84. Jeon HM, Jin X, Lee JS, Oh SY, Sohn YW, Park HJ, **Joo KM**, Park WY, Nam DH, DePinho RA, Chin L, Kim H. Inhibitor of differentiation 4 drives brain tumor-initiating cell genesis through cyclin E and notch signaling. Genes Dev. 2008 Aug 1;22(15):2028-33.
85. Chung YH, **Joo KM**, Kim DJ, Kim SS, Kim KY, Lee WB, Cha CI. Immunohistochemical study on the distribution of glycogen synthase kinase 3alpha in the central nervous system of SOD1(G93A) transgenic mice. Neurol Res. 2008 Nov;30(9):926-31. (**co-first author**)
86. Nam DH, Jeon HM, Kim S, Kim MH, Lee YJ, Lee MS, Kim H, **Joo KM**, Lee DS, Price JE, Bang SI, Park WY. Activation of notch signaling in a xenograft model of brain metastasis. Clin Cancer Res. 2008 Jul 1;14(13):4059-66.
87. **Joo KM**, Kim SY, Jin X, Song SY, Kong DS, Lee JI, Jeon JW, Kim MH, Kang BG, Jung Y, Jin J, Hong SC, Park WY, Lee DS, Kim H, Nam DH. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest. 2008 Aug;88(8):808-15.
88. Lim HC, Lee ST, Chu K, **Joo KM**, Kang L, Im WS, Park JE, Kim SU, Kim M, Cha CI. Neuroprotective effect of neural stem cell-conditioned media in in vitro model of Huntington's disease. Neurosci Lett. 2008 Apr 25;435(3):175-80.
89. **Joo KM**, Park K, Kong DS, Song SY, Kim MH, Lee GS, Kim MS, Nam DH. Oral paclitaxel chemotherapy for brain tumors: ideal combination treatment of paclitaxel and P-glycoprotein inhibitor. Oncol Rep. 2008 Jan;19(1):17-23.
90. Kong DS, Kim MH, Jeon JW, Kim SY, Kim MS, **Joo KM**, Park K, Nam DH. Antitumor activity of ZD6474 in a metastatic orthotopic brain tumor model. Mol Med Rep. 2008 May-Jun;1(3):343-6.
91. Lee SJ, Chung YH, **Joo KM**, Lim HC, Jeon GS, Kim D, Lee WB, Kim YS, Cha CI. Age-related changes in glycogen synthase kinase 3beta (GSK3beta) immunoreactivity in the central nervous system of rats. Neurosci Lett. 2006 Dec 1;409(2):134-9.
92. Choi JS, Pham TT, Jang YJ, Bui BC, Lee BH, **Joo KM**, Cha CI, Lee KH. Corticotropin-releasing factor (CRF) and urocortin promote the survival of cultured cerebellar GABAergic neurons through the type 1 CRF receptor. J Korean Med Sci. 2006 Jun;21(3):518-26.
93. **Joo KM**, Chung YH, Lim HC, Lee KH, Cha CI. Reduced immunoreactivities of a vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptor (VPAC1 receptor) in the cerebral cortex, hippocampal region, and amygdala of aged rats. Brain Res. 2005 Dec 7;1064(1-2):166-72.
94. Kim MK, Park JH, Kwon BS, **Joo KM**, Pyo JS, Cheon YH, Baik TK, Cha CI, Cho SS, Nam SY, Lee BL. Glial fibrillary acidic protein is expressed in the aged rat olfactory epithelium. Acta Otolaryngol. 2005 Aug;125(8):883-7.
95. Chung YH, **Joo KM**, Lim HC, Cho MH, Kim D, Lee WB, Cha CI. Immunohistochemical study on the distribution of phosphorylated extracellular signal-regulated kinase (ERK) in the central nervous system of SOD1G93A transgenic mice. Brain Res. 2005 Jul 19;1050(1-2):203-9.
96. Jung DK, Lee SY, Kim D, **Joo KM**, Cha CI, Yang HS, Lee WB, Chung YH. Age-related changes in the distribution of Kv1.1 and Kv3.1 in rat cochlear nuclei. Neurol Res. 2005 Jun;27(4):436-40.
97. Chung YH, **Joo KM**, Nam RH, Cho MH, Kim DJ, Lee WB, Cha CI. Decreased expression of calretinin in the cerebral cortex and hippocampus of SOD1G93A transgenic mice. Brain Res. 2005 Feb 21;1035(1):105-9.
98. Chung YH, **Joo KM**, Nam RH, Kim YS, Lee WB, Cha CI. Immunohistochemical study on the distribution of the voltage-gated potassium channels in the gerbil cerebellum. Neurosci Lett. 2005 Feb 1;374(1):58-62.
99. Kim MJ, Chung YH, **Joo KM**, Oh GT, Kim J, Lee B, Cha CI. Immunohistochemical study of the distribution of neuronal voltage-gated calcium channels in the nNOS knock-out mouse cerebellum. Neurosci Lett. 2004 Oct 7;369(1):39-43.
100. Chung YH, **Joo KM**, Nam RH, Lee WB, Lee KH, Cha CI. Region-specific alterations in insulin-like growth factor-I receptor in the central nervous system of nNOS knockout mice. Brain Res. 2004 Sep 17;1021(1):132-9.
101. **Joo KM**, Chung YH, Kim MK, Nam RH, Lee BL, Lee KH, Cha CI. Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain. J Comp Neurol. 2004 Aug 30;476(4):388-413.
102. Chung YH, Kim SI, **Joo KM**, Kim YS, Lee WB, Yun KW, Cha CI. Age-related changes in erythropoietin immunoreactivity in the cerebral cortex and hippocampus of rats. Brain Res. 2004 Aug 20;1018(1):141-6.
103. Chung YH, **Joo KM**, Kim YS, Lee KH, Lee WB, Cha CI. Enhanced expression of erythropoietin in the central nervous system of SOD1(G93A) transgenic mice. Brain Res. 2004 Aug 6;1016(2):272-80.
104. Chung YH, **Joo KM**, Lee YJ, Shin DH, Cha CI. Postnatal development and age-related changes in the distribution of nitric oxide synthase-immunoreactive neurons in the visual system of rats. Neurosci Lett. 2004 Apr 22;360(1-2):1-4.
105. Chung YH, **Joo KM**, Lee YJ, Shin DH, Cha CI. Reactive astrocytes express PARP in the central nervous system of SOD(G93A) transgenic mice. Brain Res. 2004 Apr 2;1003(1-2):199-204.
106. **Joo KM**, Chung YH, Shin CM, Lee YJ, Cha CI. Region-specific alterations of neuronal nitric oxide synthase (nNOS) expression in the amygdala of the aged rats. Brain Res. 2004 Mar 5;999(2):231-6.
107. Chung YH, **Joo KM**, Shin CM, Lee YJ, Shin DH, Lee KH, Cha CI. Immunohistochemical study on the distribution of insulin-like growth factor I (IGF-I) receptor in the central nervous system of SOD1(G93A) mutant transgenic mice. Brain Res. 2003 Dec 24;994(2):253-9.
108. Chung YH, **Joo KM**, Lee YJ, Cha CI. Immunohistochemical study on the distribution of MnSOD in the central nervous system of the transgenic mice expressing a human Cu/Zn SOD mutation. Brain Res. 2003 Nov 14;990(1-2):215-20.
109. Shin DH, Lee E, **Joo KM**, Kim J, Bae SR, Chung YH, Cha CI. Immunocytochemical study on the distribution of c-myb in the central nervous system of the transgenic mice expressing a human copper/zinc superoxide dismutase mutation. Neurosci Lett. 2003 Oct 30;350(3):149-52.
110. Chung YH, **Joo KM**, Lee YJ, Kim MJ, Cha CI. Immunohistochemical study on the aggregation of ubiquitin in the central nervous system of the transgenic mice expressing a human Cu/Zn SOD mutation. Neurol Res. 2003 Jun;25(4):395-400.
111. Chung YH, **Joo KM**, Kim MJ, Cha CI. Age-related changes in the distribution of Na(v)1.1 and Na(v)1.2 in rat cerebellum. Neuroreport. 2003 May 6;14(6):841-5.
112. Kim MJ, **Joo KM**, Chung YH, Lee YJ, Kim J, Lee BH, Shin DH, Lee KH, Cha CI. Vasoactive intestinal peptide (VIP) and VIP mRNA decrease in the cerebral cortex of nNOS knock-out(-/-) mice. Brain Res. 2003 Jul 18;978(1-2):233-40. (**co-first author**)
113. Chung YH, **Joo KM**, Lee YJ, Kim MJ, Cha CI. Reactive astrocytes express cAMP-response-element-binding protein (CREB) binding protein (CBP) in the central nervous system of transgenic mice expressing a human Cu/Zn superoxide dismutase mutation. Neurosci Lett. 2003 Jun 12;343(3):159-62.
114. Chung YH, **Joo KM**, Kim MJ, Cha CI. Immunohistochemical study on the distribution of alpha-synuclein in the central nervous system of transgenic mice expressing a human Cu/Zn superoxide dismutase mutation. Neurosci Lett. 2003 May 22;342(3):151-4.
115. Chung YH, Hong JJ, Shin CM, **Joo KM**, Kim MJ, Cha CI. Immunohistochemical study on the distribution of homocysteine in the central nervous system of transgenic mice expressing a human Cu/Zn SOD mutation. Brain Res. 2003 Mar 28;967(1-2):226-34.
116. Chung YH, Kim EJ, Shin CM, **Joo KM**, Kim MJ, Woo HW, Cha CI. Age-related changes in CREB binding protein immunoreactivity in the cerebral cortex and hippocampus of rats. Brain Res. 2002 Nov 29;956(2):312-8.
117. Chung YH, Shin CM, **Joo KM**, Kim MJ, Cha CI. Immunohistochemical study on the distribution of nitrotyrosine and neuronal nitric oxide synthase in aged rat cerebellum. Brain Res. 2002 Oct 4;951(2):316-21.
118. Chung YH, Shin CM, **Joo KM**, Kim MJ, Cha CI. Age-related upregulation of insulin-like growth factor receptor type I in rat cerebellum. Neurosci Lett. 2002 Sep 13;330(1):65-8.
119. Chung YH, Shin CM, **Joo KM**, Kim MJ, Cha CI. Region-specific alterations in insulin-like growth factor receptor type I in the cerebral cortex and hippocampus of aged rats. Brain Res. 2002 Aug 16;946(2):307-13.

**Books:**

1. Stem cell-based gene therapy in neurological disorders (A chapter in Gene Therapy in Neurological Disorders, 1st Edition, Academic Press, 25th May 2018, Hardcover ISBN: 9780128098134, Editors: Mingjie Li, B. Snider)

2. 국소해부학, 셋째판, 대한해부학회 편, 2017.1.25. (Human local anatomy, 3rd Ed., Korean Association of Anatomists, Language = Korean)

3. 7일간의 신경해부학 실습: 지침서와 아틀라스. 신동훈, 이동섭, **주경민** (**Joo KM**), 황영일. 고려의학 2010.6.1. (7 Days Neuroanatomy Lab: Guide and Atlas, Language = Korean)

4. Joo KM, Nam DH. Prospective identification of cancer stem cells with the surface antigen CD133. Methods Mol Biol. 2009;568:57-71. (A chapter in Cancer Stem Cells Methods and Protocols, #45 in the publication list)

**Patents:**

1. **Korea Patent Registration**
	1. No. 101956982 “Use of disulfiram for radiosensitizer in brain cancer” Issued Mar 5, 2019 **Joo KM** and 3 other people
	2. No. 101910269 “Method for Separating Neural Stem Cell Derived from Human Brain Tissue Having High Efficiency” Issued Oct 15, 2018 **Joo KM** and 4 other people
	3. No. 101740030 “Single-chain Fv Antibody Library, Method for Preparing Thereof and Screening Method of Single-chain Fv Antibody by Using the Same” Issued May 19, 2017 **Joo KM** and 5 other people
	4. No. 101592305 “Limiting Dilution Assay for Screening of Patient-specific Anti-cancer Agents” Issued Feb 25, 2015 **Joo KM** and 2 other people
	5. No.101536668 “Antibodies cross-reactive to Human and Mouse c-Met and Uses thereof” Issued Jul 08, 2015 **Joo KM** and 4 other people
	6. No. 101507540 “Composition for diagnosis of metastatic brain tumor” Issued Mar 25, 2015 **Joo KM** and 5 other people
	7. No. 101492436 “Patient Specific Animal model for Glioblastoma and Uses thereof” Issued Feb 02, 2015 **Joo KM** and 2 other people
	8. No. 101327533 “Novel screening System for personalized anti-cancer agents” " Issued Nov 04, 2013. **Joo KM** and 1 other people
	9. No.101269125 "Method for proliferating stem cells using genes activating notch signaling" Issued May 23, 2013. **Joo KM** and 3 other people
	10. No. 101269124 “Method for Proliferating Stem Cells Using Activating c-MET/HGF Signaling” Issued May 23, 2013. **Joo KM** and 3 other people
2. **Korea Patent Application**
	1. No. 1020180031101 “Method of isolating and culturing for neural stem Cell” Issued Mar 16, 2018. **Joo KM** and 1 other people
	2. No. 1020180031100 “Methods for Differentiating Neural Stem Cells” Issued Mar 16, 2018 **Joo KM** and 1 other people
	3. No. 1020180031099 “A Method for inducing angiogenesis using neural stem Cell” Issued Mar 16, 2018 **Joo KM** and 1 other people
3. **Foreign Patent Registration**
	1. No. 9750826 “METHOD FOR PREPARING PATIENT-SPECIFIC GLIOBLASTOMA ANIMAL MODEL, AND USES THEREOF” Issued Sep 05, 2015 **Joo KM**
	2. No. ZL201300700337 “PERSONALIZED ANTI-CANCER AGENT SCREENING SYSTEM” Issued Aug 15, 2017 **Joo KM** and 1 other people
	3. No. 11201508678S “METHOD FOR PREPARING PATIENT-SPECIFIC GLIOBLASTOMA ANIMAL MODEL, AND USES THEREOF” Issued Jun 15, 2017 **Joo KM** and 2 other people
	4. No. 9562891 “'A METHOD FOR SCREENING PATIENT-SPECIFIC ANTI-CANCER AGENT USING LIMITING DILUTION ASSAY” Issued Feb 07, 2017 **Joo KM** and 2 other people
	5. No. 2531594 “Method for Proliferating Stem Cells by Activating c-MET/HGF Signaling and Notch Signaling” Issued Noc 16, 2016 **Joo KM** and 3 other people
	6. No. 9493739 “Method for Proliferating Stem Cells by Activating c-MET/HGF Signaling and Notch Signaling” Issued Noc 15, 2016 **Joo KM** and 3 other people
	7. No. 6026653 “METHOD FOR PREPARING PATIENT-SPECIFIC GLIOBLASTOMA ANIMAL MODEL, AND USES THEREOF” Issued Oct 21, 2016 **Joo KM** and 2 other people
	8. No. 5041 “A METHOD FOR PREPARING PATIENT-SPECIFIC GLIOBLASTOMA ANIMAL MODEL, AND USES THEREOF” Issued Sep 06, 2016 **Joo KM** and 2 other people
	9. No. 4752 “NOVEL SCREENING SYSTEM FOR PERSOANLIZED ANTI-CANCER AGENTS” Issued Apr 05, 2016 **Joo KM** and 1 other people
	10. No. 9296817 “ANTIBODIES CROSS-REACTIVE TO HUMAN AND MOUSE c-Met AND USES THEREOF” Issued Mar 29, 2016 **Joo KM** and 4 other people
	11. No. 2788133 “Method for Proliferating Stem Cells by Activating c-MET/HGF Signaling and Notch Signaling” Issued Jan 26, 2016 **Joo KM** and 3 other people
	12. No. 8815581 “Method for Proliferating Stem Cells by Activating c-MET/HGF Signaling and Notch Signaling” Issued Aug 26, 2014 **Joo KM** and 3 other people
4. **Foreign Patent Application**
	1. No. 2017096417 “PERSONALIZED ANTI-CANCER dAGENT SCREENING SYSTEM” Issued May 15, 2017 **Joo KM** and 1 other people
	2. No. 138635636 “PERSONALIZED ANTI-CANCER AGENT SCREENING SYSTEM” Issued Jun 11, 2015 K **Joo KM** and 1 other people
	3. No. 11201504628U “PERSONALIZED ANTI-CANCER AGENT SCREENING SYSTEM” Issued Jun 11, 2015 **Joo KM** and 1 other people
	4. No. 14651207 “PERSONALIZED ANTI-CANCER AGENT SCREENING SYSTEM” Issued Jun 10, 2015 **Joo KM** and 1 other people
	5. No. 2015547851 “PERSONALIZED ANTI-CANCER AGENT SCREENING SYSTEM” Issued Jun 10, 2015 **Joo KM** and 1 other people
	6. No. PCT/KR2015/002262 “SCFV ANTIBODY LIBRARY, METHOD FOR PREPARING SAME, AND SCFV ANTIBODY SCREENING METHOD USING SAME” Issued Mar 9, 2015 **Joo KM** and 5 other people
	7. No. 2883922 “Method for Proliferating Stem Cells by Activating c-MET/HGF Signaling and Notch Signaling” Issued Mar 05, 2015 **Joo KM** and 3 other people
	8. No. 2013800445032 “METHOD FOR PREPARING PATIENT-SPECIFIC GLIOBLASTOMA ANIMAL MODEL, AND USES THEREOF” Issued Feb 25, 2015 **Joo KM** and 2 other people
	9. No. 138072590 “METHOD FOR PREPARING PATIENT-SPECIFIC GLIOBLASTOMA ANIMAL MODEL, AND USES THEREOF” Issued Dec 18, 2014 **Joo KM** and 2 other people
	10. No. PCTKR2014005461 “PHARMACEUTICAL COMPOSITION CONTAINING TP12 EXPRESSION INHIBITOR OR ACTIVITY INHIBITOR AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING RENAL CELL CANCER” Issued Jun 20, 2014 Kyeung Min Joo and 4 other people
	11. No. PCT/KR2013/011490 “PERSONALIZED ANTI-CANCER AGENT SCREENING SYSTEM” Issued Dec 11, 2013 **Joo KM** and 1 other people
	12. No.PCT/KR2013/005513 “METHOD FOR PREPARING PATIENT-SPECIFIC GLIOBLASTOMA ANIMAL MODEL, AND USE THEREOF” Issued Jun 21, 2013 **Joo KM** 2 other people
	13. No. PCT/KR/2011/000730 “"METHOD FOR PROLIFERATING STEM CELLS USING GENES ACTIVATING NOTCH SIGNALING” Issued Feb 01, 2011 **Joo KM** and 3 other people
	14. No. PCT/KR/2018/002253 “Method of isolating and culturing for neural stemCell” Issued Feb 23, 2018. **Joo KM** and 4 other people

**Membership:**

American Association for Cancer Research (AACR)

 - 2010-present: Active member

 - 2007-2009: Associate member

International Society for Stem Cell Research (ISSCR)

 - 2010-present: Active member

 - 2008-2009: Associate member